TRUE Private Wealth Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

TRUE Private Wealth Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-470	Closed	-$34K	–	236
2022 Q3	$34K	Sell	470 -85	-15%	-$9.57K	0.01%	215
2022 Q2	$64K	Buy	555 +60	+12%	+$8.23K	0.01%	226
2022 Q1	$79K	Buy	495 +35	+8%	+$5.08K	0.01%	237
2021 Q4	$108K	Buy	460 +190	+70%	+$39.2K	0.02%	262
2021 Q3	$59K	Buy	270 +120	+80%	+$30.8K	0.01%	244
2021 Q2	$43K	Buy	150 +30	+25%	+$9.34K	0.01%	236
2021 Q1	$46K	Buy	+120	New	+$52.4K	0.01%	232

Other funds holding SCNI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

TRUE Private Wealth Advisors's SCNI Position: Q4 2022 in Review

TRUE Private Wealth Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q4 2022, closing a stake of 470 shares — an estimated $34K sold.

TRUE Private Wealth Advisors first reported a position in SCNI in Q1 2021 and held it in 7 quarters. The position peaked at $108K in Q4 2021. 9 funds tracked by Wall St. Rank hold SCNI as of Q4 2022.

TRUE Private Wealth Advisors reported no remaining Scinai Immunotherapeutics position as of Q4 2022 after selling out during the quarter.
TRUE Private Wealth Advisors sold 470 Scinai Immunotherapeutics shares in Q4 2022, an estimated $34K.
TRUE Private Wealth Advisors first reported a position in Scinai Immunotherapeutics in Q1 2021 and held it in 7 quarters.
TRUE Private Wealth Advisors's Scinai Immunotherapeutics position peaked at $108K in Q4 2021.
9 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2022.

Based on TRUE Private Wealth Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.